Home › Free Stock Grades › NKTR
Nektar Therapeutics (NKTR) Stock Grade
NKTR · Healthcare
C-
Market Cap
$713.3M
P/E Ratio
—
Revenue Growth (YoY)
-43.9%
Net Margin
-297.1%
Return on Equity
—
Dividend Yield
None
About Nektar Therapeutics's fundamentals
Nektar Therapeutics is a biotechnology company with a market capitalization of $713.3 million that is currently unprofitable, reporting a net loss in its latest annual statement and a net margin of -297.1%. The company experienced significant revenue contraction, declining 43.9% year-over-year, indicating a substantial pullback in commercial performance. The company does not pay a dividend and lacks positive profitability metrics, which is typical for clinical-stage biotech firms but reflects meaningful financial pressure in this case.